China and India are set to drive medicine use growth in Asia, according to the IQVIA Institute’s Global Use of Medicines 2024 report. China leads with a projected 3.8% CAGR in per capita use through 2028, ranking 2nd globally in medicine spending by that year. India follows with 2.6% CAGR, placing 11th in global invoice spending by 2028. The broader Asia-Pacific region, excluding China, India, and Japan, shows mixed trends, with varying growth rates across countries. Key drivers include adoption of innovative therapies, patent expiries, and biosimilars, reshaping healthcare access and cost dynamics across the region.

Join for free to read